Data on PAT-DX1 to be presented at international summit

Latest News

Patrys (ASX:PAB), an Australian therapeutic antibody development company, has announced the upcoming presentation of scientific data regarding its lead candidate, PAT-DX1, at the PARP and DNA Damage Response (DDR) Inhibitors Summit in Boston.

The company said Dr James Hansen from the Yale School of Medicine will present at the summit next week. Ms Suzy Jones, a non-executive director of Patrys, will also be attending the summit.

Dr Hansen’s presentation is titled 'Targeting the DDR with a Nuclear-Penetrating Anti-DNA Autoantibody'. The company said it will highlight the clinical potential of PAT-DX1 by showing how it preferentially localises to tumours, crosses the blood-brain barrier, binds to DNA and inhibits the DDR.

It said the summit will also provide an opportunity to showcase the potential application of PAT-DX1 as a single agent against DDR-deficient tumours, as a sensitising agent for DNA-damaging therapies and as a nanoparticle conjugation agent (PAT-DX1-NP) to enable targeted delivery of therapeutics to improve patient outcomes.

According to CEO and managing director, Dr James Campbell, “The summit represents an important opportunity to showcase PAT-DX1’s unique mechanism of action, ability to cross the blood brain barrier and considerable promise as a potential anti-cancer therapeutic to an audience of global industry leaders. The growing international recognition of our technology reflects the leading position that Patrys and Yale are establishing in the DDR therapeutics space.”